

30 December 2016

Update on Omni Innovation Investment

EVE Investments (ASX: EVE), an ASX-listed technology investment company, is pleased to advise on the settlement of the tranche 1 placement that was announced on 23 December 2016. Proceeds from the tranche 1 placement and the previously completed placement to TRT Investment Group have been used to fund the \$1m investment into Omni Innovation which was required to be paid by 31 December 2016.

As previously advised EVE and Omni Innovation restructured the payment terms of the second tranche investment and accordingly, the balance of \$625,000 has been deferred to 28 February 2017. Once this final payment has been made EVE will hold an approximate 40% interest in Omni Innovation. A shareholder meeting to approve the tranche 2 placement will be held in early to mid February. A Notice of Meeting will be distributed to shareholders in due course.

About Omni Innovation

Omni Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases.

For more information, please visit www.omniinnovation.com.au

About EVE Investments

EVE Investment is an Australian Securities Exchange Listed Investment Company that assists emerging technology companies further develop and expand by facilitating access to capital and management expertise.

For more information, please visit www.eveinvestments.com.au

For more information:

Bill Fry

Executive Director

+61 8 6465 5500

billf@eveinvestments.com.au